美国联邦医疗保险医疗条件捆绑支付实施三年后的支出与质量:准实验双重差分研究
该准实验双重差分研究评估美国联邦医疗保险捆绑支付改进项目(BPCI)对医疗条件(急性心肌梗死、充血性心力衰竭、慢性阻塞性肺疾病、肺炎)的长期效果。226家BPCI医院与700家倾向评分匹配的非BPCI医院比较,调整分析显示参与BPCI与总 episode 支出降低1.2%(95%CI -2.3%至-0.2%)相关,专业护理机构支出降低6.3%(95%CI -10.0%至-2.5%),家庭健康支出增加4.4%(95%CI 1.4%至7.5%),90天死亡率无变化(-0.1个百分点,95%CI -0.5至0.2)。结论提示捆绑支付通过改变出院后高强度护理使用产生节约而不影响质量,且可能需要多年才能显现效果。
要点
- 在226家BPCI医院中,参与捆绑支付与总 episode 支出降低1.2%(95%CI -2.3%至-0.2%)相关。
- 专业护理机构支出降低6.3%(95%CI -10.0%至-2.5%),源于设施天数减少6.2%(95%CI -9.8%至-2.6%)。
- 家庭健康支出增加4.4%(95%CI 1.4%至7.5%)。
- 90天死亡率无变化(-0.1个百分点,95%CI -0.5至0.2)。
- 节约来自出院后高强度护理使用的实践改变,且可能需要多年才能显现。
适用人群与场景
- 美国参与BPCI的医院中,因急性心肌梗死、充血性心力衰竭、慢性阻塞性肺疾病或肺炎住院的患者。
- BPCI医院与倾向评分匹配的非BPCI医院比较。
研究设计与关键结果
- 研究设计为准实验双重差分分析,纳入238家BPCI医院和1415家非BPCI医院,其中226家BPCI医院与700家非BPCI医院匹配。
- BPCI医院基线期 episode 数261 163,治疗期93 562;匹配非BPCI医院分别为211 208和78 643。
- 调整分析显示参与BPCI与总 episode 支出降低1.2%(95%CI -2.3%至-0.2%)相关。
- 专业护理机构支出降低6.3%(95%CI -10.0%至-2.5%),设施天数减少6.2%(95%CI -9.8%至-2.6%)。
- 家庭健康支出增加4.4%(95%CI 1.4%至7.5%)。
- 90天死亡率无变化(-0.1个百分点,95%CI -0.5至0.2)。
- 部分患者特征趋势不同,如BPCI医院平均年龄变化-0.3岁 vs 非BPCI医院,P<0.001。
证据类型、等级与局限
- 证据类型:准实验双重差分分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 参与医疗条件捆绑支付与三年内总 episode 支出降低相关,节约来自出院后高强度护理使用减少而未影响90天死亡率。
- 作者认为捆绑支付对医疗条件可能需要多年才能显现支出和实践改变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate whether longer term participation in the bundled payments for care initiative (BPCI) for medical conditions in the United States, which held hospitals financially accountable for all spending during an episode of care from hospital admission to 90 days after discharge, was associated with changes in spending, mortality, or health service use.
DESIGN: Quasi-experimental difference-in-differences analysis.
SETTING: US hospitals participating in bundled payments for acute myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease (COPD), or pneumonia, and propensity score matched to non-participating hospitals.
PARTICIPANTS: 238 hospitals participating in the Bundled Payments for Care Improvement initiative (BPCI) and 1415 non-BPCI hospitals. 226 BPCI hospitals were matched to 700 non-BPCI hospitals.
MAIN OUTCOME MEASURES: Primary outcomes were total spending on episodes and death 90 days after discharge. Secondary outcomes included spending and use by type of post-acute care. BPCI and non-BPCI hospitals were compared by patient, hospital, and hospital market characteristics. Market characteristics included population size, competitiveness, and post-acute bed supply.
RESULTS: In the 226 BPCI hospitals, episodes of care totaled 261 163 in the baseline period and 93 562 in the treatment period compared with 211 208 and 78 643 in the 700 matched non-BPCI hospitals, respectively, with small differences in hospital and market characteristics after matching. Differing trends were seen for some patient characteristics (eg, mean age change -0.3 years at BPCI hospitals v non- BPCI hospitals, P<0.001). In the adjusted analysis, participation in BPCI was associated with a decrease in total episode spending (-1.2%, 95% confidence interval -2.3% to -0.2%). Spending on care at skilled nursing facilities decreased (-6.3%, -10.0% to -2.5%) owing to a reduced number of facility days (-6.2%, -9.8% to -2.6%), and home health spending increased (4.4%, 1.4% to 7.5%). Mortality at 90 days did not change (-0.1 percentage points, 95% confidence interval -0.5 to 0.2 percentage points).
CONCLUSIONS: In this longer term evaluation of a large national programme on medical bundled payments in the US, participation in bundles for four common medical conditions was associated with savings at three years. The savings were generated by practice changes that decreased use of high intensity care after hospital discharge without affecting quality, which also suggests that bundles for medical conditions could require multiple years before changes in savings and practice emerge.
参考来源
- Rolnick JA, Liao JM, Emanuel EJ, et al. Spending and quality after three years of Medicare's bundled payments for medical conditions: quasi-experimental difference-in-differences study. BMJ. 2020. PMID: 32554705. doi:10.1136/bmj.m1780
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。